Journey Medical Corporation (DERM)
NASDAQ: DERM · Real-Time Price · USD
6.62
+0.40 (6.43%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Journey Medical Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Journey Medical stock have an average target of 13.5, with a low estimate of 12 and a high estimate of 16. The average target predicts an increase of 103.93% from the current stock price of 6.62.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 14, 2026.
Analyst Ratings
The average analyst rating for Journey Medical stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Alliance Global Partners | Alliance Global Partners | Buy Reiterates $16 | Buy | Reiterates | $16 | +141.69% | May 14, 2026 |
| Lake Street | Lake Street | Buy Maintains $13 | Buy | Maintains | $13 | +96.37% | May 14, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $13 | Buy | Reiterates | $13 | +96.37% | May 14, 2026 |
| B. Riley Securities | B. Riley Securities | Buy Reiterates $12 | Buy | Reiterates | $12 | +81.27% | Mar 26, 2026 |
Financial Forecast
Revenue This Year
82.62M
from 61.86M
Increased by 33.57%
Revenue Next Year
137.73M
from 82.62M
Increased by 66.70%
EPS This Year
n/a
EPS Next Year
n/a
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 86.3M | 157.9M | |
| Avg | 82.6M | 137.7M | |
| Low | 78.6M | 120.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 39.6% | 91.1% | |
| Avg | 33.6% | 66.7% | |
| Low | 27.1% | 45.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
EPS Growth
| EPS Growth | 2027 | 2028 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.